-
Signature
-
By: /s/ Jo Chen, as Attorney-in-Fact for Eric Venker
-
Issuer symbol
-
ROIV
-
Transactions as of
-
09 Oct 2025
-
Net transactions value
-
-$55,514
-
Form type
-
4
-
Filing time
-
14 Oct 2025, 21:00:10 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Venker Eric |
President & Immunovant CEO |
C/O ROIVANT SCIENCES LTD., 7TH FLOOR, 50 BROADWAY, LONDON, UNITED KINGDOM |
By: /s/ Jo Chen, as Attorney-in-Fact for Eric Venker |
14 Oct 2025 |
0001801917 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
ROIV |
Common Shares |
Options Exercise |
$1,663,299 |
+104,940 |
+7% |
$15.85 |
1,609,899 |
09 Oct 2025 |
Direct |
|
| transaction |
ROIV |
Common Shares |
Sale |
$1,710,522 |
-104,940 |
-6.5% |
$16.30 |
1,504,959 |
09 Oct 2025 |
Direct |
F1 |
| transaction |
ROIV |
Common Shares |
Options Exercise |
$328,523 |
+20,727 |
+1.4% |
$15.85 |
1,525,686 |
13 Oct 2025 |
Direct |
|
| transaction |
ROIV |
Common Shares |
Sale |
$336,814 |
-20,727 |
-1.4% |
$16.25 |
1,504,959 |
13 Oct 2025 |
Direct |
F1 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
ROIV |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-104,940 |
-11% |
$0.000000 |
872,110 |
09 Oct 2025 |
Common Stock |
104,940 |
$15.85 |
Direct |
F2 |
| transaction |
ROIV |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-20,727 |
-2.4% |
$0.000000 |
851,383 |
13 Oct 2025 |
Common Stock |
20,727 |
$15.85 |
Direct |
F2 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: